Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neurofibromatosis 1 | 51 | 2024 | 561 | 9.180 |
Why?
|
Optic Nerve Glioma | 7 | 2024 | 32 | 2.410 |
Why?
|
Brain Neoplasms | 29 | 2024 | 9118 | 1.730 |
Why?
|
Progeria | 6 | 2016 | 188 | 1.680 |
Why?
|
Neurofibroma, Plexiform | 9 | 2022 | 66 | 1.650 |
Why?
|
Neurofibromatoses | 10 | 2023 | 303 | 1.150 |
Why?
|
Neurocutaneous Syndromes | 2 | 2015 | 53 | 0.940 |
Why?
|
School Health Services | 2 | 2018 | 388 | 0.910 |
Why?
|
Cranial Irradiation | 5 | 2022 | 393 | 0.900 |
Why?
|
Moyamoya Disease | 4 | 2013 | 274 | 0.890 |
Why?
|
Neurofibromatosis 2 | 7 | 2023 | 388 | 0.890 |
Why?
|
Craniopharyngioma | 5 | 2020 | 279 | 0.870 |
Why?
|
Nervous System Diseases | 5 | 2017 | 1662 | 0.860 |
Why?
|
Radiation Injuries | 3 | 2018 | 1198 | 0.860 |
Why?
|
Child | 94 | 2024 | 80917 | 0.850 |
Why?
|
Neurilemmoma | 8 | 2023 | 522 | 0.790 |
Why?
|
Glioma | 11 | 2020 | 3503 | 0.770 |
Why?
|
Radiotherapy | 7 | 2017 | 1502 | 0.750 |
Why?
|
Brain Stem Neoplasms | 3 | 2015 | 191 | 0.730 |
Why?
|
Neurotoxicity Syndromes | 2 | 2024 | 302 | 0.730 |
Why?
|
Survivors | 12 | 2023 | 2381 | 0.730 |
Why?
|
Nerve Sheath Neoplasms | 3 | 2023 | 169 | 0.720 |
Why?
|
Antineoplastic Agents | 11 | 2020 | 13677 | 0.640 |
Why?
|
Cell Adhesion Molecules | 2 | 2015 | 1613 | 0.630 |
Why?
|
Child, Preschool | 48 | 2024 | 42669 | 0.630 |
Why?
|
Medulloblastoma | 4 | 2017 | 683 | 0.620 |
Why?
|
Neoplasms | 18 | 2023 | 22371 | 0.620 |
Why?
|
Neurology | 2 | 2020 | 786 | 0.610 |
Why?
|
Adolescent | 70 | 2024 | 89169 | 0.610 |
Why?
|
Infratentorial Neoplasms | 3 | 2017 | 99 | 0.580 |
Why?
|
Neurofibromin 1 | 4 | 2020 | 190 | 0.580 |
Why?
|
Diabetes Insipidus | 2 | 2019 | 144 | 0.570 |
Why?
|
Clitoris | 1 | 2017 | 35 | 0.560 |
Why?
|
Spasm | 1 | 2017 | 131 | 0.560 |
Why?
|
Seizures | 7 | 2024 | 2998 | 0.550 |
Why?
|
Visual Acuity | 5 | 2020 | 2714 | 0.550 |
Why?
|
Chloride Channels | 5 | 1998 | 221 | 0.530 |
Why?
|
Ependymoma | 5 | 2021 | 328 | 0.530 |
Why?
|
Central Nervous System Neoplasms | 5 | 2023 | 928 | 0.520 |
Why?
|
Glioblastoma | 8 | 2010 | 3464 | 0.520 |
Why?
|
Paresis | 1 | 2017 | 176 | 0.510 |
Why?
|
Disabled Children | 1 | 2018 | 250 | 0.500 |
Why?
|
Leukemia, B-Cell | 1 | 2015 | 86 | 0.490 |
Why?
|
Medical Oncology | 3 | 2023 | 2346 | 0.490 |
Why?
|
Vitamin B 12 Deficiency | 1 | 2016 | 119 | 0.480 |
Why?
|
Antigens, CD | 2 | 2015 | 4035 | 0.470 |
Why?
|
Brain Abscess | 1 | 2015 | 123 | 0.470 |
Why?
|
Astrocytoma | 7 | 2017 | 774 | 0.470 |
Why?
|
Stroke | 5 | 2023 | 9755 | 0.460 |
Why?
|
Infant | 33 | 2024 | 36535 | 0.450 |
Why?
|
Mutism | 1 | 2014 | 27 | 0.450 |
Why?
|
Thorax | 1 | 2017 | 557 | 0.450 |
Why?
|
Epilepsy | 3 | 2024 | 3326 | 0.440 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2015 | 257 | 0.440 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2015 | 342 | 0.420 |
Why?
|
Humans | 141 | 2024 | 768171 | 0.410 |
Why?
|
Pituitary Diseases | 1 | 2013 | 137 | 0.390 |
Why?
|
Bone Diseases, Developmental | 1 | 2013 | 132 | 0.390 |
Why?
|
Neurofibrosarcoma | 2 | 2023 | 28 | 0.380 |
Why?
|
Neuroectodermal Tumors, Primitive | 2 | 2017 | 137 | 0.380 |
Why?
|
Piperidines | 4 | 2016 | 1667 | 0.380 |
Why?
|
Neuropsychological Tests | 6 | 2020 | 7140 | 0.370 |
Why?
|
Hearing Loss | 3 | 2024 | 785 | 0.370 |
Why?
|
Pyridines | 4 | 2021 | 2894 | 0.370 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 3251 | 0.360 |
Why?
|
Male | 77 | 2024 | 364731 | 0.350 |
Why?
|
Pituitary Gland | 1 | 2013 | 634 | 0.350 |
Why?
|
Cerebral Revascularization | 1 | 2013 | 260 | 0.340 |
Why?
|
Lovastatin | 3 | 2020 | 115 | 0.340 |
Why?
|
Eye Abnormalities | 1 | 2012 | 243 | 0.340 |
Why?
|
Craniofacial Abnormalities | 1 | 2012 | 320 | 0.330 |
Why?
|
Skin Neoplasms | 9 | 2023 | 5863 | 0.320 |
Why?
|
Female | 74 | 2024 | 397187 | 0.310 |
Why?
|
Acupressure | 2 | 2018 | 16 | 0.310 |
Why?
|
Delphi Technique | 3 | 2023 | 890 | 0.310 |
Why?
|
Skull | 1 | 2013 | 829 | 0.300 |
Why?
|
Optic Disk | 1 | 2012 | 421 | 0.300 |
Why?
|
Neuroma, Acoustic | 2 | 2023 | 455 | 0.290 |
Why?
|
Consensus | 7 | 2023 | 3211 | 0.290 |
Why?
|
Angiogenesis Inhibitors | 3 | 2019 | 2057 | 0.290 |
Why?
|
Young Adult | 33 | 2024 | 60066 | 0.290 |
Why?
|
Memory Disorders | 2 | 2017 | 1200 | 0.290 |
Why?
|
Medical Records | 1 | 2013 | 1410 | 0.290 |
Why?
|
Play and Playthings | 1 | 2008 | 85 | 0.290 |
Why?
|
Angiography | 1 | 2012 | 1597 | 0.280 |
Why?
|
Parents | 2 | 2018 | 3595 | 0.280 |
Why?
|
Pseudotumor Cerebri | 1 | 2008 | 107 | 0.280 |
Why?
|
Retrospective Studies | 31 | 2024 | 81760 | 0.280 |
Why?
|
Brain Damage, Chronic | 1 | 2008 | 265 | 0.280 |
Why?
|
Neurosurgical Procedures | 6 | 2024 | 2077 | 0.270 |
Why?
|
Melanoma | 2 | 2015 | 5706 | 0.270 |
Why?
|
Myelitis, Transverse | 1 | 2006 | 40 | 0.270 |
Why?
|
Cerebrovascular Disorders | 1 | 2012 | 1485 | 0.250 |
Why?
|
Killer Cells, Natural | 1 | 2015 | 2211 | 0.250 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2008 | 249 | 0.240 |
Why?
|
Nausea | 2 | 2018 | 682 | 0.240 |
Why?
|
Referral and Consultation | 1 | 2018 | 3620 | 0.240 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2010 | 709 | 0.240 |
Why?
|
Patient Education as Topic | 2 | 2014 | 2337 | 0.230 |
Why?
|
Cerebral Arteries | 1 | 2007 | 488 | 0.230 |
Why?
|
Pituitary Neoplasms | 3 | 2020 | 1322 | 0.230 |
Why?
|
Migraine Disorders | 1 | 2017 | 1713 | 0.230 |
Why?
|
Quality of Life | 11 | 2023 | 13490 | 0.230 |
Why?
|
Internship and Residency | 2 | 2020 | 5953 | 0.220 |
Why?
|
Motor Skills Disorders | 1 | 2004 | 89 | 0.220 |
Why?
|
Hypothalamic Diseases | 1 | 2005 | 134 | 0.220 |
Why?
|
Amnesia, Transient Global | 1 | 2003 | 19 | 0.220 |
Why?
|
Genetic Association Studies | 5 | 2019 | 2744 | 0.220 |
Why?
|
Cisplatin | 2 | 2020 | 1660 | 0.220 |
Why?
|
User-Computer Interface | 1 | 2010 | 1407 | 0.210 |
Why?
|
Vision Disorders | 3 | 2016 | 1092 | 0.210 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2012 | 2055 | 0.210 |
Why?
|
Diagnosis, Differential | 8 | 2019 | 13013 | 0.210 |
Why?
|
Airway Obstruction | 1 | 2008 | 672 | 0.200 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 2 | 2022 | 637 | 0.200 |
Why?
|
Disability Evaluation | 1 | 2010 | 1835 | 0.200 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2012 | 2846 | 0.200 |
Why?
|
Pediatrics | 4 | 2020 | 3629 | 0.190 |
Why?
|
Electroencephalography | 4 | 2017 | 6314 | 0.190 |
Why?
|
Cafe-au-Lait Spots | 2 | 2021 | 20 | 0.190 |
Why?
|
Developmental Disabilities | 2 | 2008 | 1518 | 0.190 |
Why?
|
Mutation, Missense | 3 | 2019 | 2592 | 0.180 |
Why?
|
Pseudarthrosis | 1 | 2021 | 54 | 0.180 |
Why?
|
Sirolimus | 2 | 2020 | 1540 | 0.180 |
Why?
|
Clinical Trials as Topic | 5 | 2019 | 8052 | 0.180 |
Why?
|
Thiosulfates | 1 | 2020 | 52 | 0.180 |
Why?
|
Adult | 33 | 2024 | 223646 | 0.170 |
Why?
|
Supratentorial Neoplasms | 2 | 2019 | 156 | 0.170 |
Why?
|
Treatment Outcome | 16 | 2023 | 65379 | 0.170 |
Why?
|
Steroids | 1 | 2024 | 938 | 0.160 |
Why?
|
Bone Morphogenetic Protein 2 | 1 | 2021 | 344 | 0.160 |
Why?
|
Education, Medical, Graduate | 1 | 2011 | 2420 | 0.160 |
Why?
|
Cognition Disorders | 2 | 2012 | 3980 | 0.160 |
Why?
|
Practice Guidelines as Topic | 3 | 2021 | 7454 | 0.150 |
Why?
|
Maze Learning | 1 | 2020 | 482 | 0.150 |
Why?
|
Stem Cell Transplantation | 1 | 2006 | 1599 | 0.150 |
Why?
|
Pyrimidinones | 1 | 2020 | 386 | 0.150 |
Why?
|
Anilides | 1 | 2021 | 413 | 0.150 |
Why?
|
Meningeal Neoplasms | 1 | 2007 | 1253 | 0.150 |
Why?
|
Huntington Disease | 1 | 2004 | 1147 | 0.140 |
Why?
|
Magnetic Resonance Imaging | 13 | 2020 | 36741 | 0.140 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2021 | 9419 | 0.140 |
Why?
|
Radiography | 4 | 2013 | 6986 | 0.140 |
Why?
|
Psychotropic Drugs | 2 | 2012 | 881 | 0.140 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2024 | 1560 | 0.140 |
Why?
|
Cerebellar Neoplasms | 2 | 2019 | 591 | 0.140 |
Why?
|
Disease Progression | 6 | 2023 | 13668 | 0.130 |
Why?
|
Optic Nerve Neoplasms | 1 | 2016 | 45 | 0.130 |
Why?
|
Antiemetics | 1 | 2017 | 188 | 0.130 |
Why?
|
Scoliosis | 1 | 2023 | 793 | 0.130 |
Why?
|
Codon | 1 | 2017 | 599 | 0.130 |
Why?
|
Bacillus cereus | 1 | 2015 | 36 | 0.130 |
Why?
|
Leukoencephalopathies | 1 | 2019 | 259 | 0.130 |
Why?
|
Prospective Studies | 13 | 2024 | 54924 | 0.130 |
Why?
|
Rhabdoid Tumor | 2 | 2008 | 211 | 0.130 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6669 | 0.120 |
Why?
|
Clinical Competence | 1 | 2011 | 4858 | 0.120 |
Why?
|
Tibia | 2 | 2021 | 1076 | 0.120 |
Why?
|
Follow-Up Studies | 14 | 2020 | 39354 | 0.120 |
Why?
|
Prognosis | 11 | 2020 | 30009 | 0.120 |
Why?
|
Incidental Findings | 1 | 2020 | 698 | 0.120 |
Why?
|
Pyridones | 1 | 2020 | 819 | 0.120 |
Why?
|
Hospitals, Pediatric | 1 | 2024 | 1876 | 0.120 |
Why?
|
Twins, Monozygotic | 1 | 2016 | 472 | 0.120 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2015 | 94 | 0.120 |
Why?
|
Models, Educational | 1 | 2017 | 375 | 0.120 |
Why?
|
Social Behavior | 1 | 2021 | 1147 | 0.120 |
Why?
|
Hyperalgesia | 1 | 2019 | 527 | 0.120 |
Why?
|
Patch-Clamp Techniques | 4 | 1998 | 927 | 0.120 |
Why?
|
Telemedicine | 2 | 2023 | 3109 | 0.110 |
Why?
|
Pravastatin | 1 | 2016 | 393 | 0.110 |
Why?
|
Survival Rate | 8 | 2019 | 12840 | 0.110 |
Why?
|
Visual Fields | 1 | 2020 | 1065 | 0.110 |
Why?
|
Lamin Type A | 1 | 2015 | 190 | 0.110 |
Why?
|
Protein Kinase Inhibitors | 4 | 2022 | 5704 | 0.110 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 9262 | 0.110 |
Why?
|
Risk Factors | 11 | 2018 | 74944 | 0.110 |
Why?
|
Oculomotor Muscles | 1 | 2017 | 405 | 0.110 |
Why?
|
Postoperative Care | 1 | 2020 | 1480 | 0.110 |
Why?
|
GPI-Linked Proteins | 1 | 2015 | 472 | 0.110 |
Why?
|
Chlorides | 1 | 1996 | 666 | 0.110 |
Why?
|
Vision Tests | 1 | 2013 | 160 | 0.110 |
Why?
|
Transforming Growth Factor beta | 1 | 2021 | 2004 | 0.100 |
Why?
|
Tumor Cells, Cultured | 6 | 1998 | 6124 | 0.100 |
Why?
|
Farnesyltranstransferase | 1 | 2012 | 71 | 0.100 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2008 | 3626 | 0.100 |
Why?
|
Interferon-alpha | 1 | 2017 | 910 | 0.100 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2018 | 716 | 0.100 |
Why?
|
Cytoskeleton | 1 | 1997 | 1179 | 0.100 |
Why?
|
Visual Pathways | 1 | 2016 | 557 | 0.100 |
Why?
|
Faculty, Medical | 2 | 2012 | 1226 | 0.100 |
Why?
|
Executive Function | 2 | 2019 | 1401 | 0.100 |
Why?
|
Surgery, Computer-Assisted | 1 | 2019 | 1003 | 0.100 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2020 | 2062 | 0.090 |
Why?
|
Rare Diseases | 3 | 2022 | 631 | 0.090 |
Why?
|
Diphosphonates | 1 | 2016 | 634 | 0.090 |
Why?
|
Attention | 3 | 2016 | 2423 | 0.090 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2015 | 1353 | 0.090 |
Why?
|
Polyethylene Glycols | 1 | 2017 | 1197 | 0.090 |
Why?
|
Liver Neoplasms | 1 | 2007 | 4363 | 0.090 |
Why?
|
Brain Diseases | 1 | 2020 | 1554 | 0.090 |
Why?
|
Orthopedic Procedures | 1 | 2021 | 1279 | 0.090 |
Why?
|
Aspirin | 1 | 2022 | 3135 | 0.090 |
Why?
|
Imidazoles | 1 | 2016 | 1169 | 0.090 |
Why?
|
Immunocompromised Host | 1 | 2015 | 863 | 0.090 |
Why?
|
Protein Isoforms | 1 | 2015 | 1715 | 0.090 |
Why?
|
Feasibility Studies | 2 | 2020 | 5315 | 0.090 |
Why?
|
Recoverin | 1 | 2009 | 11 | 0.090 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 3 | 2021 | 3729 | 0.090 |
Why?
|
Germinoma | 1 | 2010 | 132 | 0.080 |
Why?
|
Attitude of Health Personnel | 1 | 2003 | 3929 | 0.080 |
Why?
|
Chlamydomonas reinhardtii | 1 | 2009 | 35 | 0.080 |
Why?
|
Starch | 1 | 2009 | 81 | 0.080 |
Why?
|
DNA Modification Methylases | 1 | 2010 | 208 | 0.080 |
Why?
|
DNA Methylation | 2 | 2023 | 4428 | 0.080 |
Why?
|
Stress, Psychological | 2 | 2017 | 4530 | 0.080 |
Why?
|
Obesity, Morbid | 1 | 2020 | 1298 | 0.080 |
Why?
|
Cell Cycle | 1 | 1997 | 2934 | 0.080 |
Why?
|
Disease-Free Survival | 6 | 2016 | 6847 | 0.080 |
Why?
|
Cognition | 4 | 2021 | 7073 | 0.080 |
Why?
|
Age Factors | 4 | 2014 | 18415 | 0.080 |
Why?
|
Meningioma | 1 | 2018 | 1220 | 0.080 |
Why?
|
Research | 2 | 2014 | 1979 | 0.080 |
Why?
|
Base Sequence | 2 | 2020 | 12422 | 0.080 |
Why?
|
Incidence | 4 | 2024 | 21538 | 0.080 |
Why?
|
Patient Selection | 1 | 2021 | 4260 | 0.080 |
Why?
|
Asymptomatic Diseases | 1 | 2011 | 590 | 0.080 |
Why?
|
DNA Repair Enzymes | 1 | 2010 | 343 | 0.080 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2015 | 1361 | 0.080 |
Why?
|
Alleles | 1 | 2019 | 6894 | 0.080 |
Why?
|
Cross-Sectional Studies | 6 | 2024 | 26379 | 0.080 |
Why?
|
Spinal Neoplasms | 1 | 2014 | 715 | 0.070 |
Why?
|
Biomedical Research | 1 | 2003 | 3463 | 0.070 |
Why?
|
Pinealoma | 1 | 2008 | 52 | 0.070 |
Why?
|
Organ Size | 1 | 2013 | 2267 | 0.070 |
Why?
|
Retinal Detachment | 1 | 2012 | 429 | 0.070 |
Why?
|
Infant, Newborn | 5 | 2020 | 26421 | 0.070 |
Why?
|
Ligands | 1 | 2015 | 3284 | 0.070 |
Why?
|
Disease Management | 2 | 2018 | 2535 | 0.070 |
Why?
|
Spinal Cord | 1 | 2016 | 1812 | 0.070 |
Why?
|
DNA Copy Number Variations | 1 | 2016 | 2048 | 0.070 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2015 | 1657 | 0.070 |
Why?
|
Heterozygote | 3 | 2019 | 2798 | 0.070 |
Why?
|
Down-Regulation | 1 | 2015 | 2939 | 0.070 |
Why?
|
Brain | 3 | 2020 | 27362 | 0.070 |
Why?
|
Scorpion Venoms | 2 | 1998 | 30 | 0.070 |
Why?
|
Combined Modality Therapy | 5 | 2017 | 8542 | 0.070 |
Why?
|
Pineal Gland | 1 | 2008 | 158 | 0.070 |
Why?
|
Circle of Willis | 1 | 2007 | 77 | 0.070 |
Why?
|
Transfection | 1 | 2015 | 5756 | 0.070 |
Why?
|
Cohort Studies | 6 | 2020 | 41753 | 0.070 |
Why?
|
Health Promotion | 1 | 2019 | 2210 | 0.070 |
Why?
|
Optic Chiasm | 1 | 2007 | 91 | 0.070 |
Why?
|
Mentors | 1 | 2012 | 671 | 0.070 |
Why?
|
Choroid Plexus Neoplasms | 1 | 2006 | 38 | 0.070 |
Why?
|
Heart Defects, Congenital | 1 | 2003 | 4712 | 0.070 |
Why?
|
Morbidity | 2 | 2023 | 1755 | 0.070 |
Why?
|
Chronic Disease | 2 | 2021 | 9384 | 0.070 |
Why?
|
In Situ Hybridization | 1 | 2010 | 1904 | 0.070 |
Why?
|
Head | 1 | 2012 | 926 | 0.060 |
Why?
|
Psychomotor Performance | 1 | 2014 | 1892 | 0.060 |
Why?
|
Gene Dosage | 1 | 2010 | 1219 | 0.060 |
Why?
|
Up-Regulation | 1 | 2015 | 4149 | 0.060 |
Why?
|
Teratoma | 1 | 2008 | 405 | 0.060 |
Why?
|
Vomiting | 2 | 2023 | 655 | 0.060 |
Why?
|
Cell Membrane | 1 | 2015 | 3655 | 0.060 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2010 | 498 | 0.060 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2007 | 876 | 0.060 |
Why?
|
Polysomnography | 1 | 2012 | 1871 | 0.060 |
Why?
|
Hospitals | 1 | 2018 | 3886 | 0.060 |
Why?
|
PTEN Phosphohydrolase | 1 | 2010 | 1120 | 0.060 |
Why?
|
Intelligence | 1 | 2009 | 926 | 0.060 |
Why?
|
Antiviral Agents | 1 | 2017 | 3072 | 0.060 |
Why?
|
Comorbidity | 3 | 2024 | 10590 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 2 | 2014 | 6525 | 0.060 |
Why?
|
Prejudice | 1 | 2008 | 574 | 0.050 |
Why?
|
Audiometry | 1 | 2024 | 253 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 10397 | 0.050 |
Why?
|
Research Support as Topic | 1 | 2008 | 696 | 0.050 |
Why?
|
Pain | 1 | 2019 | 5099 | 0.050 |
Why?
|
Cyanosis | 1 | 2003 | 82 | 0.050 |
Why?
|
Protein Binding | 1 | 2015 | 9343 | 0.050 |
Why?
|
Palliative Care | 1 | 2018 | 3643 | 0.050 |
Why?
|
Drug Prescriptions | 1 | 2012 | 1668 | 0.050 |
Why?
|
Autopsy | 1 | 2007 | 1011 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 3 | 2019 | 18065 | 0.050 |
Why?
|
Research Personnel | 1 | 2008 | 589 | 0.050 |
Why?
|
Molecular Biology | 1 | 2006 | 573 | 0.050 |
Why?
|
Hydrocephalus | 1 | 2009 | 768 | 0.050 |
Why?
|
Molecular Sequence Data | 1 | 2015 | 17623 | 0.050 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2021 | 5717 | 0.050 |
Why?
|
Disease Models, Animal | 3 | 2021 | 18349 | 0.050 |
Why?
|
Polycythemia | 1 | 2003 | 124 | 0.050 |
Why?
|
Occipital Lobe | 1 | 2004 | 376 | 0.050 |
Why?
|
Animals | 9 | 2021 | 169285 | 0.050 |
Why?
|
Biopsy | 2 | 2008 | 6792 | 0.050 |
Why?
|
Age of Onset | 2 | 2012 | 3346 | 0.050 |
Why?
|
Lung Neoplasms | 1 | 2007 | 13586 | 0.050 |
Why?
|
Fatal Outcome | 1 | 2007 | 1836 | 0.050 |
Why?
|
Stress, Physiological | 1 | 2009 | 1408 | 0.050 |
Why?
|
Time Factors | 5 | 2014 | 40220 | 0.050 |
Why?
|
Radiopharmaceuticals | 1 | 2012 | 2735 | 0.050 |
Why?
|
Enzyme Inhibitors | 1 | 2012 | 3728 | 0.050 |
Why?
|
Academic Medical Centers | 1 | 2012 | 2785 | 0.050 |
Why?
|
Physicians, Women | 1 | 2008 | 517 | 0.050 |
Why?
|
Pilot Projects | 2 | 2018 | 8741 | 0.050 |
Why?
|
Headache | 1 | 2009 | 1263 | 0.050 |
Why?
|
Reproducibility of Results | 1 | 2019 | 20225 | 0.050 |
Why?
|
Drug Design | 1 | 2006 | 1046 | 0.050 |
Why?
|
Population Surveillance | 1 | 2011 | 2596 | 0.050 |
Why?
|
Thalidomide | 1 | 2006 | 886 | 0.050 |
Why?
|
Lipid Metabolism | 1 | 2009 | 1904 | 0.050 |
Why?
|
Genes, Neurofibromatosis 1 | 1 | 2021 | 74 | 0.040 |
Why?
|
Middle Aged | 8 | 2021 | 223487 | 0.040 |
Why?
|
Survival Analysis | 2 | 2017 | 10099 | 0.040 |
Why?
|
Carotid Arteries | 2 | 2016 | 942 | 0.040 |
Why?
|
Nerve Fibers | 1 | 2024 | 709 | 0.040 |
Why?
|
Tumor Suppressor Proteins | 1 | 2010 | 2810 | 0.040 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2010 | 2956 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2015 | 8648 | 0.040 |
Why?
|
Pain Measurement | 2 | 2021 | 3583 | 0.040 |
Why?
|
Cell Division | 2 | 1997 | 4477 | 0.040 |
Why?
|
Research Report | 2 | 2012 | 369 | 0.040 |
Why?
|
Recombinant Proteins | 2 | 2021 | 6512 | 0.040 |
Why?
|
Fellowships and Scholarships | 1 | 2008 | 1135 | 0.040 |
Why?
|
Boston | 2 | 2014 | 9374 | 0.040 |
Why?
|
Lipids | 1 | 2009 | 3345 | 0.040 |
Why?
|
Cell Line, Tumor | 1 | 2015 | 17142 | 0.040 |
Why?
|
Hypotonic Solutions | 1 | 1997 | 48 | 0.040 |
Why?
|
Retinal Ganglion Cells | 1 | 2024 | 811 | 0.040 |
Why?
|
Mice, Mutant Strains | 1 | 2021 | 1754 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 11878 | 0.040 |
Why?
|
Thymidine | 1 | 1997 | 297 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2019 | 10763 | 0.040 |
Why?
|
Sample Size | 1 | 2021 | 846 | 0.040 |
Why?
|
Neurotoxins | 1 | 1998 | 240 | 0.030 |
Why?
|
Membrane Potentials | 2 | 1997 | 1090 | 0.030 |
Why?
|
Dexamethasone | 1 | 2024 | 1965 | 0.030 |
Why?
|
Nystagmus, Pathologic | 1 | 2017 | 104 | 0.030 |
Why?
|
4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 1996 | 59 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 15453 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 2010 | 11095 | 0.030 |
Why?
|
Protein Prenylation | 1 | 2016 | 70 | 0.030 |
Why?
|
Genetic Heterogeneity | 1 | 2020 | 736 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2007 | 4913 | 0.030 |
Why?
|
Spine | 1 | 2023 | 1140 | 0.030 |
Why?
|
Recurrence | 1 | 2008 | 8509 | 0.030 |
Why?
|
Phenotype | 3 | 2019 | 16726 | 0.030 |
Why?
|
Mutation | 3 | 2016 | 30237 | 0.030 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2021 | 846 | 0.030 |
Why?
|
Genomics | 2 | 2023 | 5926 | 0.030 |
Why?
|
Electric Conductivity | 1 | 1996 | 407 | 0.030 |
Why?
|
Stilbenes | 1 | 1996 | 155 | 0.030 |
Why?
|
Mice | 3 | 2021 | 82049 | 0.030 |
Why?
|
Amino Acid Substitution | 1 | 2019 | 1743 | 0.030 |
Why?
|
Pain Threshold | 1 | 2019 | 606 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2024 | 14783 | 0.030 |
Why?
|
Logistic Models | 2 | 2012 | 13290 | 0.030 |
Why?
|
Education, Special | 1 | 2014 | 86 | 0.030 |
Why?
|
Sequence Deletion | 1 | 2018 | 1497 | 0.030 |
Why?
|
Indans | 1 | 2014 | 92 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2019 | 12466 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2017 | 1587 | 0.030 |
Why?
|
Anticonvulsants | 1 | 2024 | 1923 | 0.030 |
Why?
|
Injections, Spinal | 1 | 2014 | 317 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2021 | 1628 | 0.030 |
Why?
|
Nootropic Agents | 1 | 2014 | 159 | 0.030 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2018 | 620 | 0.030 |
Why?
|
Tetrodotoxin | 1 | 1994 | 243 | 0.030 |
Why?
|
Strabismus | 1 | 2017 | 320 | 0.030 |
Why?
|
Demography | 1 | 2017 | 1641 | 0.030 |
Why?
|
Mice, SCID | 1 | 1998 | 2627 | 0.030 |
Why?
|
Antioxidants | 1 | 2020 | 1676 | 0.030 |
Why?
|
Histones | 1 | 2023 | 2601 | 0.030 |
Why?
|
United States | 5 | 2022 | 73039 | 0.030 |
Why?
|
Sodium Channels | 1 | 1994 | 341 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1793 | 0.020 |
Why?
|
SEER Program | 1 | 2017 | 1444 | 0.020 |
Why?
|
Aged | 4 | 2021 | 171502 | 0.020 |
Why?
|
Language | 1 | 2021 | 1557 | 0.020 |
Why?
|
Women, Working | 1 | 2012 | 86 | 0.020 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 1 | 1994 | 480 | 0.020 |
Why?
|
Ganglia, Spinal | 1 | 1994 | 529 | 0.020 |
Why?
|
Cerebellum | 1 | 2019 | 1522 | 0.020 |
Why?
|
Thinking | 1 | 2014 | 320 | 0.020 |
Why?
|
Delivery of Health Care | 2 | 2023 | 5367 | 0.020 |
Why?
|
Vinblastine | 1 | 2012 | 487 | 0.020 |
Why?
|
Health Services Needs and Demand | 1 | 2018 | 1406 | 0.020 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2014 | 646 | 0.020 |
Why?
|
Caregivers | 1 | 2023 | 2302 | 0.020 |
Why?
|
Tomography, Optical Coherence | 1 | 2024 | 2957 | 0.020 |
Why?
|
Bone Density | 1 | 2023 | 3573 | 0.020 |
Why?
|
Methylphenidate | 1 | 2014 | 480 | 0.020 |
Why?
|
Algal Proteins | 1 | 2009 | 7 | 0.020 |
Why?
|
Actins | 1 | 1997 | 2064 | 0.020 |
Why?
|
Chromatography, Thin Layer | 1 | 2009 | 212 | 0.020 |
Why?
|
Chromatography, Gas | 1 | 2009 | 150 | 0.020 |
Why?
|
alpha-Fetoproteins | 1 | 2010 | 229 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 1998 | 2393 | 0.020 |
Why?
|
Obesity | 1 | 2012 | 13091 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2015 | 59626 | 0.020 |
Why?
|
Vincristine | 1 | 2012 | 1040 | 0.020 |
Why?
|
Congresses as Topic | 1 | 2014 | 812 | 0.020 |
Why?
|
Postoperative Period | 1 | 2014 | 1826 | 0.020 |
Why?
|
Human Growth Hormone | 1 | 2014 | 651 | 0.020 |
Why?
|
Carboplatin | 1 | 2012 | 797 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2015 | 15662 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2016 | 4620 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2021 | 3490 | 0.020 |
Why?
|
Nitrogen | 1 | 2009 | 345 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2017 | 15949 | 0.020 |
Why?
|
Genetic Testing | 1 | 2021 | 3591 | 0.020 |
Why?
|
Computational Biology | 1 | 2020 | 3567 | 0.020 |
Why?
|
Memory, Short-Term | 1 | 2014 | 1007 | 0.020 |
Why?
|
Methotrexate | 1 | 2014 | 1721 | 0.020 |
Why?
|
Sex Factors | 2 | 2014 | 10632 | 0.020 |
Why?
|
Benzhydryl Compounds | 1 | 2014 | 944 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2014 | 2916 | 0.020 |
Why?
|
Learning | 1 | 2016 | 1759 | 0.020 |
Why?
|
Flow Cytometry | 1 | 1997 | 5902 | 0.020 |
Why?
|
Quality Improvement | 1 | 2022 | 3857 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 3239 | 0.020 |
Why?
|
Proteomics | 1 | 2020 | 3912 | 0.020 |
Why?
|
Astrocytes | 1 | 1994 | 1350 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2016 | 6316 | 0.020 |
Why?
|
Cell Line | 2 | 1997 | 15602 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2017 | 13422 | 0.020 |
Why?
|
Reference Standards | 1 | 2009 | 1014 | 0.020 |
Why?
|
Central Nervous System Stimulants | 1 | 2014 | 1168 | 0.020 |
Why?
|
Diarrhea | 1 | 2012 | 1320 | 0.020 |
Why?
|
Bone and Bones | 1 | 2016 | 2590 | 0.020 |
Why?
|
Staining and Labeling | 1 | 2009 | 1080 | 0.020 |
Why?
|
Fatigue | 1 | 2012 | 1557 | 0.020 |
Why?
|
Drug Therapy | 1 | 2008 | 504 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2012 | 4861 | 0.010 |
Why?
|
Computer Simulation | 1 | 2017 | 6283 | 0.010 |
Why?
|
Salvage Therapy | 1 | 2010 | 1273 | 0.010 |
Why?
|
Awards and Prizes | 1 | 2008 | 365 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2007 | 20762 | 0.010 |
Why?
|
Body Mass Index | 1 | 2020 | 13053 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2009 | 2634 | 0.010 |
Why?
|
Mass Spectrometry | 1 | 2009 | 2202 | 0.010 |
Why?
|
Weight Gain | 1 | 2012 | 2359 | 0.010 |
Why?
|
Genotype | 1 | 2016 | 13045 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2017 | 11244 | 0.010 |
Why?
|
Triglycerides | 1 | 2009 | 2464 | 0.010 |
Why?
|
Secondary Prevention | 1 | 2008 | 1474 | 0.010 |
Why?
|
Schools, Medical | 1 | 2008 | 883 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8747 | 0.010 |
Why?
|
Treatment Failure | 1 | 2006 | 2661 | 0.010 |
Why?
|
Head and Neck Neoplasms | 1 | 2014 | 2931 | 0.010 |
Why?
|
Cells, Cultured | 2 | 2009 | 19025 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2016 | 12795 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2016 | 16044 | 0.010 |
Why?
|
Prevalence | 1 | 2012 | 15869 | 0.010 |
Why?
|
Strophanthidin | 1 | 1994 | 15 | 0.010 |
Why?
|
Rubidium | 1 | 1994 | 121 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2009 | 14729 | 0.010 |
Why?
|
Ouabain | 1 | 1994 | 246 | 0.010 |
Why?
|
Electrophysiology | 1 | 1994 | 1266 | 0.010 |
Why?
|
Sodium | 1 | 1994 | 1597 | 0.000 |
Why?
|
Animals, Newborn | 1 | 1994 | 2683 | 0.000 |
Why?
|
Rats, Sprague-Dawley | 1 | 1994 | 8142 | 0.000 |
Why?
|
Rats | 1 | 1994 | 23782 | 0.000 |
Why?
|
Models, Biological | 1 | 1994 | 9497 | 0.000 |
Why?
|